Cost-effectiveness of the treatment of respiratory diseases of xiyanping injection : A systematic review

Objectives: To systematically review the economic evaluations of the Xiyanping injection to treat respiratory diseases. Methods: Database as PubMed, ISI Web of knowledge, The Cochrane Library, CBM, WanFang Data, CNKI and VIP were electronically searched from inception to February 28st, 2014. Two reviewers independently screened studies according to inclusion and exclusion criteria and extracted data. Then, descriptive analysis was performed for included studies. A 10-item quality checklist modified was used to appraise the quality of studies. Results: 6 economic evaluations and cost studies were included of which 4 studies' quality were low, 1 was high and 1 was medium. All studies adequately documented effectiveness of interventions. However, the costs of interventions were not well reported in 2 studies. 2 studies inadequately conducted sensitivity analysis and discounting. The disease of 6 studies includingbronchitis(2studies), upper respiratory tract infection, herpangina, hand-foot-and-mouth disease and viral pneumonia. The studies result showed that cost-effectiveness of Xiyanping injection is poor than Tanreqing injection and have more adverse reaction in 2 studies and It is poor than Yanhuning injection, but less adverse reaction in 2 studies. Xiyanping injection is better than anti-viral medicine in 2 studies. 1study indicated that Xiyanping is more cost-effectiveness by atomized than intravenous drip. Conclusions: Xiyanping injection is not better than other proprietary Chinese medicine for the treatment of respiratory diseases in costeffectiveness analysis, however it is better than anti-viral medicine, and less adverse reaction. The quality of included studies is weaken the conclusion. There remains a strong need to improve the quality of reporting.